Comparative Pharmacology
Head-to-head clinical analysis: MECLAN versus VIBRAMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MECLAN versus VIBRAMYCIN.
MECLAN vs VIBRAMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meclizine is an antihistamine with central anticholinergic properties. It blocks histamine H1 receptors and exerts antiemetic effects via inhibition of the vestibular system and chemoreceptor trigger zone.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing addition of amino acids to the growing peptide chain. Bacteriostatic.
250 mg orally three times daily for 7-14 days; for sinusitis: 500 mg three times daily.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg once daily; severe infections: 100 mg every 12 hours.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours in adults; prolonged in renal impairment (up to 30 hours).
Terminal elimination half-life is 16-18 hours in patients with normal renal function. Prolonged to 20-36 hours in severe renal impairment; no significant change in hepatic impairment.
Renal excretion of unchanged drug and metabolites: ~70%; fecal/biliary: ~30%.
Approximately 40% excreted unchanged in urine via glomerular filtration; 20-25% eliminated in feces via biliary secretion; remainder metabolized. Renal clearance is about 30 mL/min.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic